Jamshid Mian, MD
Family Medicine · Baltimore, MDNPI 1538143953
Payments from drug & device makers
Across 334 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$817
- Dexcom, Inc.$486
- Pfizer$363
- Lilly USA, LLC$357
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,061100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 78 | $1,250 |
| AstraZeneca | 56 | $1,224 |
| Novo Nordisk | 36 | $817 |
| Dexcom, Inc. | 8 | $486 |
| Pfizer | 22 | $363 |
| Lilly USA, LLC | 21 | $357 |
| Abbott | 13 | $336 |
| Bayer | 10 | $290 |
| GSK | 15 | $267 |
| Silk Road Medical, Inc. | 1 | $178 |
| Sanofi-aventis U.S. LLC | 4 | $157 |
| Novartis | 10 | $142 |
| Amgen | 7 | $141 |
| Boehringer Ingelheim | 6 | $128 |
| UCB, Inc. | 4 | $106 |
| E.r. Squibb & Sons, L.L.C. | 2 | $97 |
| Exact Sciences | 5 | $94 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $75 |
| Phadia US Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $52 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $47 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| Biogen | 1 | $27 |
| Merck | 2 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Watermark Medical, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Insulet Corporation | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Orexo US, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,061 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 37 | $41,090 |
| EliquisApixaban | 52 | $39,748 |
| JanuviaSitagliptin Phosphate | 42 | $30,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $22,822 |
| TrulicityDulaglutide | 13 | $18,665 |
| XareltoRivaroxaban | 15 | $17,534 |
| LinzessLinaclotide | 27 | $15,873 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 24 | $15,864 |
| Nurtec OdtRimegepant Sulfate | 15 | $13,253 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,122 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 144 | $6,288 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $5,096 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $4,175 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $4,008 |
| Epinephrine | 17 | $3,127 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $363 | $53,00167 claims |
| Novo NordiskOzempic | $817 | $41,09037 claims |
| MerckJanuvia | $24 | $30,44742 claims |
| GSKTrelegy Ellipta | $267 | $22,82229 claims |
| Lilly USA, LLCTrulicity | $357 | $18,66513 claims |
| AbbVieLinzess | $1,250 | $15,87327 claims |
| Boehringer IngelheimCombivent Respimat | $128 | $15,86424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Baltimore
- Karen DonaldsonBaltimore$899K
- Louis JacquesBaltimore$522K
- Michael ObiefuneBaltimore$291K
- Daljeet SalujaBaltimore$63K
- Fernando PorterBaltimore$54K
- Richard ColganBaltimore$31K
- Stacy GarrettBaltimore$20K
- Nishant ShahBaltimore$17K
- Diaa MikhailBaltimore$15K
- Yaniv BergerBaltimore$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.